Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.
A R MüllerB den HollanderP M van de VenK C B RoesL GeertjensH BruiningC D M van KarnebeekF E JansenM C Y de WitL W Ten HoopenA B RietmanB DierckxF A WijburgE BootM M G BrandsA M van EeghenPublished in: BMC psychiatry (2024)
EudraCT: 2021-003250-23, registered 25 August 2022, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003250-23/NL .